The Bio/Pharmaceutical Outsourcing Report highlights opportunities in strategic planning for CMO executives, insights for bio/pharma sourcing executives, and investment targets for investors. Key ...

The MarketWatch News Department was not involved in the creation of this content. HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. The ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a ...

This news release contains certain forward-looking statements relating to STARJEMZA ® /BAT2206 or the product pipelines in general of Bio-Thera Solutions and Hikma. Readers are strongly cautioned that ...

The global biopharmaceutical community is preparing to gather in Lisbon, Portugal, for the 20th edition of BIO-Europe Spring®, the premier springtime partnering conference for the industry, taking ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price ...

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and ...

LNK01006 reflects Lynk Pharmaceuticals' medicinal chemistry expertise, incorporating a highly optimized scaffold engineered for target selectivity, metabolic stability, and CNS penetration. "We are ...